20126 ⎘
Medicinal preparations characterised by special physical form; Pills, tablets, discs, rods; Dragees; Coated pills or tablets, e.g. with film or compression coating; Coating materials; Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone Poly(meth)acrylates
Pharmaceutical compositions of duloxetine
#902Method for production of coated preparations
#903Mixed metal compounds used as antacids
#904BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS
#905Modified release compositions of milnacipran
#906Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
#907Citrate salt of Rasagiline
#908Delayed release rasagiline malate formulation
#909Delayed release rasagiline formulation
#910Delayed release rasagiline base formulation
#911Delayed release rasagiline citrate formulation
#912Method to maintain the efficacy of orlistat
#913SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER
#914Compositions to treat bacterial and inflammatory affections in pet animals dosage form and method to treat pet animals
#915Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole
#916Pharmaceutical formulation containing gelling agent
#917Methods and Compositions for the Treatment of Viral Infections
#918STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALINE
#919MEDICAMENT IN A MULTILAYER FORM
#920Tranexamic acid formulations
#921Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
#922DOSAGE FORMS OF RISEDRONATE
#923Low dosage forms of risedronate or its salts
#924Low dosage forms of risedronate or its salts
#925EXTENDED RELEASE FORMULATIONS OF A PROTON PUMP INHIBITOR
#926Tacrolimus for improved treatment of transplant patients
#927Pharmaceutical Compositions Containing Diacerein
#928Bupropion hydrobromide and therapeutic applications
#929Process for the preparation of sevelamer hydrochloride and formulation thereof
#930Dosage forms of bisphosphonates
#931High-loading, controlled-release magnesium oral dosage forms and methods of making and using same
#932PROCESS FOR PRODUCTION OF TABLET
#933Delayed Release Formulations for Oral Administration of a Polypeptide Therapeutic Agent and Methods of Using Same
#934PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT
#935ORGANIC COMPOUNDS
#936IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE
#937Solid oral dosage form containing an enhancer
#938Dried and/or microencapsulated cells with a high content of (s)-(+)-s-adenosyl-l-methionine, process for their preparation, and compositons containing said cells
#939Solid oral dosage form containing an enhancer
#940PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN DERIVATIVES
#941Once-a-day (RNA-Polymerase Inhibiting or phenazine) - dihydropteroate synthase inhibiting - dihydrofolate reductase inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by Methicillin-Resistant Staphylococcus aureus
#942Crush-Resistant Tablets Intended to Prevent Accidental Misuse and Unlawful Diversion
#943Solid dispersions comprising tacrolimus
#944COMPOSITION AND COMBINATIONS OF CARBOXYLIC ACID LOSARTAN IN DOSAGE FORMS
#945Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
#946PHARMACEUTICAL COMPOSITIONS FOR THE ORAL OR RECTAL ADMINISTRATION OF PROTEIN SUBSTANCES
#947SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE
#948ENTERIC COATED HYDROPHOBIC MATRIX FORMULATION
#949Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine
#950METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS
#951Peptide pharmaceutical for oral delivery
#952Water-insoluble, iron-containing mixed metal, granular material
#953Pharmaceutical formulation
#954CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#955DRUG DELIVERY COMPOSITION
#956Oral formulations of cytidine analogs and methods of use thereof
#957Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor
#958Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
#959Process for the preparation of sevelamer hydrochloride and formulation thereof
#960Compositions of GnRH related compounds and processes of preparation
#961Compositions of peptides and processes of preparation thereof
#962Method of measuring coating quantity and method of predicting dissolution behavior
#963LEVETIRACETAM FORMULATIONS
#964NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF
#965COMPOSITION AND METHOD FOR BINDING ACETALDEHYDE IN STOMACH
#966Treatment of Gastroparesis and Nonulcer Dyspepsia With GABAB Agonists
#967QUININE DOSAGE FORMS AND METHODS OF USE THEREOF
#968Controlled release delivery device comprising an organosol coat
#969Stable Oral Pharmaceutical Composition Containing Thyroid Hormone Receptor Agonists
#970Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic-analgesic drug and proton pump inhibitor
#971FORMULATIONS CONTAINING PANTOPRAZOLE FREE ACID AND ITS SALTS
#972TRANEXAMIC ACID FORMULATIONS
#973Octanol Formulations and Methods of Treatment Using the Same
#974TRANEXAMIC ACID FORMULATIONS WITH REDUCED ADVERSE EFFECTS
#975Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
#976Pharmaceutical Composition Of Acid Labile Substances
#977BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS
#978CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE
#979ENTERIC SUSTAINED-RELEASE COATED CORE AND PHARMACEUTICAL DOSAGE FORM AND METHOD FOR MANUFACTURING THE SAME
#980Pharmaceutical formulations of amyloid inhibiting compounds
#981Utilization of dialkylfumarates
#982EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#983PH-controlled pulsatile delivery system, methods for preparation and use thereof
#984Rasagiline formulations, their preparation and use
#985Utilization of dialkylfumarates
#986Misuse preventative, controlled release formulation
#987Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
#988Formulation and method for the release of paroxetine in the large intestine
#989MESALAZINE TABLET
#990PULSED-RELEASE PREPARATION HAVING IMPROVED DISINTEGRATION PROPERTIES IN VIVO
#991Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions
#992PHARMACEUTICAL DOSAGE FORMS COMPRISING A LOW-SOLUBILITY DRUG AND A POLYMER
#993Controlled release dosage forms
#994SUSTAINED-RELEASE PREPARATIONS AND METHOD FOR PRODUCING THE SAME
#995Modified release niacin formulations
#996Controlled Release Compositions of an Antidepressant Agent
#997Extracts of L., the compositions comprising said extracts, the preparing process and application thereof
#998Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
#999Oral Controlled Release Formulation for Sedatives and Hypnotic Agents
#1000Liposome Drug Delivery
#1001Compositions and Methods for Enhancement of Sexual Function
#1002TROFOSFAMIDE-CONTAINING FILM-COATED TABLETS AND METHOD FOR THE PRODUCTION THEREOF
#1003Novel nifedipine compositions
#1004Pharmaceutical composition containing gelling agent
#1005Enterically coated cystamine, cysteamine and derivatives thereof
#1006Oral formulations of glycyl-2-methylprolyl-glutamate
#1007ORALLY ADMINSTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT
#1008Azithromycin for treatment of skin disorders
#1009Controlled release azithromycin solid dosages forms
#1010Novel nifedipine compositions
#1011Delayed release formulations of 6-mercaptopurine
#1012Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases
#1013Partly neutralised anionic (meth) acrylate copolymer
#1014Mesalamine Formulations
#1015Tablet with remedial composition and methods for treating medical disorders and ailments
#1016Pharmaceutical compositions of rifaximin
#1017CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF
#1018Composition Containing Anti-Dementia Drug
#1019Modified release compositions of milnacipran
#1020Spherical Menthol Particles
#1021Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion
#1022Controlled release and taste masking oral pharmaceutical composition
#1023Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
#1024STABLE ORAL FORMULATION CONTAINING BENZIMIDAZOLE DERIVATIVE
#1025Controlled Slow Release Formulation of Thiamine and Use Thereof in the Treatment of Pathologies Connected to Defective Process of Learning and Memorization
#1026Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders
#1027Dosage forms for movement disorder treatment
#1028Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
#1029CONTROLLED RELEASE FORMULATIONS USING INTELLIGENT POLYMERS
#1030Enteric Sustained-Release Tablet Comprising Paroxetine
#1031Low Dosage Forms Of Risedronate Or Its Salts
#1032Low Dosage Forms Of Risedronate Or Its Salts
#1033Pharmaceutical compositions containing terbinafin and use thereof
#1034Solid oral dosage form containing an enhancer
#1035Bupropion hydrobromide and therapeutic applications
#1036CONTROLLED RELEASE DOSAGE FORMS
#1037Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients
#1038Oral dosage formulations of protease-resistant polypeptides
#1039Controlled Absorption of Statins in the Intestine
#1040PHARMACEUTICAL COMPOSITION OF TOPIRAMATE
#1041PAROXETINE COMPOSITIONS
#1042Pharmaceutical Active-Ingredient-Containing Formulation with Coating
#1043Osmotically-driven fluid dispenser
#1044Pharmaceutical Compositions Comprising Danazol
#1045COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS
#1046ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS
#1047Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide
#1048Fumaric Acid Derivatives as NF-kappaB Inhibitor
#1049Combination of Rosiglitazone and Donepezil for Improvement of Cognitive Function
#1050Controlled Release Pharmaceutical Compositions of Tolperisone for Oral Administration
#1051Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles
#1052CONTROLLED RELEASE NISOLDIPINE COMPOSITIONS
#1053Once daily dosage forms of trospium
#1054Method of treating bladder dysfunction with once-a-day trospium salt formulation
#1055Trospium chloride treatment method
#1056Once daily dosage forms of trospium
#1057Therapeutic materials and methods
#1058Pharmaceutical compositions for sleep disorders
#1059Use of a partially neutralized, anionic (meth) acrylate copolymer as a coating for the production of a medicament pharmaceutical form releasing active substance at reduced pH values
#1060Extended Release Venlafaxine Compositions
#1061Controlled release dosage form of tacrolimus
#1062ORALLY ADMINISTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT
#1063Dosage forms for administering combinations of drugs
#1064Oral formulations
#1065Pharmaceutical Formulations
#1066PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION APOMORPHINE, 6AR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF
#1067Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors
#1068Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
#1069Topiramate compositions and methods of enhancing its bioavailability
#1070Modified release formulations of a bupropion salt
#1071Bupropion hydrobromide and therapeutic applications
#1072Controlled release nisoldipine compositions
#1073STABLE TABLET DOSAGE FORMS OF PROTON PUMP INHIBITORS
#1074Controlled Release Formulations
#1075Modified release formulations of a bupropion salt
#1076COLON-TARGETED ORAL FORMULATIONS OF CYTIDINE ANALOGS
#1077Modified release formulations of a bupropion salt
#1078ORALLY ADMINISTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT
#1079Modified release formulations of a bupropion salt
#1080Modified release formulations of a bupropion salt
#1081Modified release formulations of a bupropion salt
#1082Enteric Coating Compositions
#1083Modified release formulations of a bupropion salt
#1084Modified release formulations of a bupropion salt
#1085Sustained-release bupropion and bupropion/mecamylamine tablets
#1086Controlled-release pharmaceutical tablets
#1087PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN INSULIN SENSITISER AND ANOTHER ANTIDIABETIC AGENT
#1088Modified Release Tablet Formulations for Proton Pump Inhibitors
#1089Controlled-Release Formulation Comprising Tamsulosin Hydrochloride
#1090Modified release formulations of a bupropion salt
#1091Solid Oral Dosage Form Containing an Enhancer
#1092PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE INSULIN SENSITISER
#1093MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT
#1094Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
#1095Modified release formulations of a bupropion salt
#1096Methods and compositions for the treatment of viral infections
#1097Modified release formulations of a bupropion salt
#1098Enteric Coated Pharmaceutical Oral Formulations Comprising Acid-Labile Active Substances, and a Method Thereof
#1099Modified release tablets comprising tramadol
#1100Pharmaceutical formulations
#1101Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
#1102Solid dosage formulations
#1103Oral antimicrobial pharmaceutical compositions
#1104Utilization of dialkylfumarates
#1105Utilization of dialkylfumarates
#1106Quetiapine formulations
#1107Novel formulation of pyridoxal-5'-phosphate and method of preparation
#1108Lubricious coatings for pharmaceutical applications
#1109Oral dosage forms including an antiplatelet agent and an acid inhibitor
#1110Solid oral dosage form containing an enhancer
#1111Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof
#1112PHARMACEUTICAL FORMULATIONS OF 6-11 BICYCLIC MACROLIDE DERIVATIVE KNOWN AS EDP-182 AND METHODS FOR PREPARATION THEREOF
#1113Controlled Release Pharmaceutical Formulation
#1114Dosage Form Having Polymorphic Stability
#1115ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION
#1116Sustained release matrix systems for highly soluble drugs
#1117Oral controlled release formulation for sedative and hypnotic agents
#1118PHARMACEUTICAL COMPOSITIONS AND METHODS TO ACHIEVE AND MAINTAIN A TARGETED AND STABLE COPPER STATUS AND PREVENT AND TREAT COPPER-RELATED CENTRAL NERVOUS SYSTEM DISEASES
#1119Stable oral formulation containing benzimidazole derivative
#1120Poorly water-soluble drug-containing solid formulation
#1121Pharmaceutical compositions containing flibanserin
#1122Magnesium microtablets with sustained release
#1123Solid oral dosage form containing an enhancer
#1124Stabilized atorvastatin
#1125Sustained release dosage forms of ziprasidone
#1126Pharmaceutical formulations
#1127Coating process to produce controlled release coatings
#1128Modified release formulations of tramadol and uses thereof
#1129Dipyridamole extended-release formulations and process for preparing same
#1130Levodopa compositions
#1131Coated tablet containing venlafaxin or its salts with controlled release
#1132Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
#1133Pharmaceutical preparations for treating hypertension and dyslipidemia with Allium ursinum and Allium sativum
#1134Solid ganaxolone formulations and methods for the making and use thereof
#1135Dosage forms for movement disorder treatment
#1136Pharmaceutical formulations
#1137Solid oral dosage form containing an enhancer
#1138Liquid ganaxolone formulations and methods for the making and use thereof
#1139Orally administered pharmaceutical composition
#1140Pharmaceutical composition
#1141Composition for releasing a weak base for an extended period of time
#1142Pharmaceutical formulations
#1143Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders
#1144QUININE DOSAGE FORMS AND METHODS OF USE THEREOF
#1145Extended release osmo-microsealed formulation
#1146Methylene Blue Therapy of Parasitic Infections
#1147Enteric coated aliphatic amine polymer bile acid sequestrants
#1148Methods and compositions for oral administration of proteins
#1149Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin
#1150Modified release formulations of a bupropion salt
#1151Benzimidazole formulation
#1152STABLE DESLORATADINE COMPOSITIONS
#1153Dosage forms for movement disorder treatment
#1154Enteric delivery of (-)-hydroxycitric acid
#1155Modified release compositions comprising tacrolimus
#1156Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer
#1157PHARMACEUTICAL COMPOSITION OF TOPIRAMATE
#1158Powder coating composition for electrostatic coating of pharmaceutical substrates
#1159Pharmaceutical formulations
#1160Pharmaceutical formulations
#1161Delivery and formulations of mast cell stabilizers
#1162Quinine dosage forms and methods of use thereof
#1163Quinine formulations
#1164Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
#1165Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
#1166Controlled release bupropion dosage forms
#1167Pharmaceutical formulations of amyloid inhibiting compounds
#1168Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
#1169Pharmaceutical formulations of amyloid inhibiting compounds
#1170Enteric coated composition comprising prostaglandin analogs as chloride channel opener
#1171Modified release tablet of bupropion hydrochloride
#1172Metformin methods and formulations for treating chronic constipation
#1173Sustained release ranolazine formulations
#1174Dosage form containing (s)-pantoprazole as active ingredient
#1175Stable tablet dosage forms of proton pump inhibitors
#1176Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
#1177Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers
#1178Tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration
#1179Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
#1180Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
#1181Composition and method for treating neurological disease
#1182Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
#1183Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
#1184Antidepressant oral pharmaceutical compositions
#1185Method for producing a controlled release preparation
#1186Controlled release and taste masking oral pharmaceutical composition
#1187Dosage forms with an enterically coated core tablet
#1188Sustained-release preparations and method for producing the same
#1189Sustained release ranolazine formulations
#1190Enteric film coating composition containing enteric polymer micronized with detackifier
#1191Controlled release and taste masking oral pharmaceutical composition
#1192Solvent free taste masked pharmaceutical compositions
#1193Dosage forms of risedronate
#1194Methods and formulations for making controlled release oral dosage form
#1195Methods and formulations for making controlled release oral dosage form
#1196Methods and formulations for making pharmaceutical compositions containing bupropion
#1197Controlled drug delivery systems providing variable release rates
#1198Liposome drug delivery
#1199Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
#1200Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent